Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exagen (XGN) Revenue (2018 - 2026)

Exagen filings provide 9 years of Revenue readings, the most recent being $17.3 million for Q1 2026.

  • On a quarterly basis, Revenue rose 11.67% to $17.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $68.4 million, a 20.55% increase, with the full-year FY2025 number at $66.6 million, up 19.65% from a year prior.
  • Revenue hit $17.3 million in Q1 2026 for Exagen, up from $16.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $17.3 million in Q1 2026 to a low of $7.6 million in Q2 2022.
  • Median Revenue over the past 5 years was $14.1 million (2023), compared with a mean of $14.0 million.
  • Biggest five-year swings in Revenue: crashed 40.45% in 2022 and later surged 85.87% in 2023.
  • Exagen's Revenue stood at $12.8 million in 2022, then rose by 7.23% to $13.8 million in 2023, then dropped by 0.8% to $13.7 million in 2024, then rose by 21.79% to $16.6 million in 2025, then increased by 4.06% to $17.3 million in 2026.
  • The last three reported values for Revenue were $17.3 million (Q1 2026), $16.6 million (Q4 2025), and $17.2 million (Q3 2025) per Business Quant data.